miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy.
miRNAs and lncRNAs as Novel Therapeutic Targets to Improve Cancer Immunotherapy.
复制标题
DOI：
10.3390/cancers13071587
复制
发表时间：
2021-03-30
期刊：
影响因子：
5.2
通讯作者：
Tassone P
中科院分区：
文献类型：
--
作者：
Di Martino MT;Riillo C;Scionti F;Grillone K;Polerà N;Caracciolo D;Arbitrio M;Tagliaferri P;Tassone P
免疫系统的高度失调促进了癌症的发作和进展。最近，在分子和临床癌症免疫学方面取得了重大进展，为治疗常见肿瘤提供了新的药物，在延长生存期甚至治愈方面往往具有惊人的益处。不幸的是，大多数肿瘤仍然对当前的免疫治疗方法具有抗性，并且迫切期待抗性机制的基本知识。我们将注意力集中在非编码RNA上，这是一类通过选择性靶向关键分子通路来调节许多生物学过程的RNA，最近，它们在癌细胞免疫逃逸和肿瘤微环境调节中的作用得到了鉴定，表明它们作为有希望的免疫靶点的功能。在这种情况下，我们指出，非编码RNA正在逐步成为免疫调节剂，我们描绘了目前的信息复杂的网络，涉及免疫系统和非编码RNA和有前途的治疗方案正在调查。新的机会正在出现从非编码RNA用于治疗免疫难治性肿瘤。免疫疗法是目前研究和开发用于治疗癌症的最有前途的领域之一。虽然免疫检查点阻断单克隆抗体和基于嵌合抗原受体（CAR）T细胞的治疗最近在某些情况下提供了有价值的治疗选择，但大多数恶性肿瘤的治愈目标尚未实现，迫切需要更多的努力。非编码RNA（ncRNA），包括microRNA（miRNAs）和长链非编码RNA（lncRNA），通过选择性靶向关键的分子信号通路来调节多种生物学过程。最近，miRNA和lncRNA作为癌症免疫应答调节剂的关键作用已经逐渐显现，因为它们可以（i）通过塑造内在肿瘤细胞和微环境（TME）特性;（ii）通过调节血管生成、免疫逃逸、上皮向间质转化、侵袭和耐药性;和（iii）作为预后评估和预测对免疫疗法的反应的潜在生物标志物。在这篇综述中，我们提供了一个概述ncRNA在调节免疫反应和TME的作用。我们讨论了ncRNA作为潜在生物标志物或作为新疗法开发或临床转化靶点的潜在用途。最后，我们讨论了基于ncRNA靶向剂和肿瘤免疫检查点抑制剂抗体或CAR-T的潜在组合方法，用于人类癌症的实验性治疗。
Cancer onset and progression are promoted by high deregulation of the immune system. Recently, major advances in molecular and clinical cancer immunology have been achieved, offering new agents for the treatment of common tumors, often with astonishing benefits in terms of prolonged survival and even cure. Unfortunately, most tumors are still resistant to current immune therapy approaches, and basic knowledge of the resistance mechanisms is eagerly awaited. We focused our attention on noncoding RNAs, a class of RNA that regulates many biological processes by targeting selectively crucial molecular pathways and that, recently, had their role in cancer cell immune escape and modulation of the tumor microenvironment identified, suggesting their function as promising immunotherapeutic targets. In this scenario, we point out that noncoding RNAs are progressively emerging as immunoregulators, and we depict the current information on the complex network involving the immune system and noncoding RNAs and the promising therapeutic options under investigation. Novel opportunities are emerging from noncoding-RNAs for the treatment of immune-refractory tumors. Immunotherapy is presently one of the most promising areas of investigation and development for the treatment of cancer. While immune checkpoint-blocking monoclonal antibodies and chimeric antigen receptor (CAR) T-cell-based therapy have recently provided in some cases valuable therapeutic options, the goal of cure has not yet been achieved for most malignancies and more efforts are urgently needed. Noncoding RNAs (ncRNA), including microRNAs (miRNAs) and long noncoding RNAs (lncRNAs), regulate several biological processes via selective targeting of crucial molecular signaling pathways. Recently, the key roles of miRNA and lncRNAs as regulators of the immune-response in cancer have progressively emerged, since they may act (i) by shaping the intrinsic tumor cell and microenvironment (TME) properties; (ii) by regulating angiogenesis, immune-escape, epithelial-to-mesenchymal transition, invasion, and drug resistance; and (iii) by acting as potential biomarkers for prognostic assessment and prediction of response to immunotherapy. In this review, we provide an overview on the role of ncRNAs in modulating the immune response and the TME. We discuss the potential use of ncRNAs as potential biomarkers or as targets for development or clinical translation of new therapeutics. Finally, we discuss the potential combinatory approaches based on ncRNA targeting agents and tumor immune-checkpoint inhibitor antibodies or CAR-T for the experimental treatment of human cancer.
登录
查看更多内容
影响因子：
56.9
作者：
Carninci, P;Kasukawa, T;Hayashizaki, Y
通讯作者：
Hayashizaki, Y
LNMAT1 通过 CCL2 依赖性巨噬细胞募集促进膀胱癌淋巴转移
影响因子：
16.6
作者：
Chen C;He W;Huang J;Wang B;Li H;Cai Q;Su F;Bi J;Liu H;Zhang B;Jiang N;Zhong G;Zhao Y;Dong W;Lin T
通讯作者：
Lin T
DOI：
10.1016/j.omtn.2017.06.005
发表时间：
2017-09-15
期刊：
Molecular therapy. Nucleic acids
影响因子：
--
作者：
Chakraborty C;Sharma AR;Sharma G;Doss CGP;Lee SS
通讯作者：
Lee SS
影响因子：
4
作者：
Cai T;Liu Y;Xiao J
通讯作者：
Xiao J
影响因子：
3.4
作者：
Beg MS;Brenner AJ;Sachdev J;Borad M;Kang YK;Stoudemire J;Smith S;Bader AG;Kim S;Hong DS
通讯作者：
Hong DS